WO2001049867A1 - M cell directed vaccines - Google Patents
M cell directed vaccines Download PDFInfo
- Publication number
- WO2001049867A1 WO2001049867A1 PCT/US2001/000426 US0100426W WO0149867A1 WO 2001049867 A1 WO2001049867 A1 WO 2001049867A1 US 0100426 W US0100426 W US 0100426W WO 0149867 A1 WO0149867 A1 WO 0149867A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vaccine
- cell
- protein
- cells
- nucleic acid
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 75
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 134
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 96
- 239000003446 ligand Substances 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 40
- 230000003053 immunization Effects 0.000 claims abstract description 22
- 241001465754 Metazoa Species 0.000 claims abstract description 21
- 230000036039 immunity Effects 0.000 claims abstract description 18
- 210000000981 epithelium Anatomy 0.000 claims abstract description 14
- 239000012678 infectious agent Substances 0.000 claims abstract description 13
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 11
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 11
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 10
- 201000011510 cancer Diseases 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 150
- 150000007523 nucleic acids Chemical group 0.000 claims description 52
- 102000039446 nucleic acids Human genes 0.000 claims description 50
- 108020004707 nucleic acids Proteins 0.000 claims description 50
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 230000002163 immunogen Effects 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 36
- 108091007433 antigens Proteins 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 239000000427 antigen Substances 0.000 claims description 34
- 230000014509 gene expression Effects 0.000 claims description 30
- 230000027455 binding Effects 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 239000013598 vector Substances 0.000 claims description 28
- 229920001184 polypeptide Polymers 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 20
- 241000702263 Reovirus sp. Species 0.000 claims description 18
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 claims description 18
- 230000028993 immune response Effects 0.000 claims description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
- 229920000642 polymer Polymers 0.000 claims description 16
- 239000002671 adjuvant Substances 0.000 claims description 11
- 229920000656 polylysine Polymers 0.000 claims description 11
- 230000001681 protective effect Effects 0.000 claims description 9
- 241000607142 Salmonella Species 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- 108010039918 Polylysine Proteins 0.000 claims description 7
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000002103 transcriptional effect Effects 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 238000013518 transcription Methods 0.000 claims description 5
- 230000035897 transcription Effects 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 241000991587 Enterovirus C Species 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 210000004400 mucous membrane Anatomy 0.000 claims description 4
- 244000045947 parasite Species 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 241000222722 Leishmania <genus> Species 0.000 claims description 3
- 206010024229 Leprosy Diseases 0.000 claims description 3
- 241000712079 Measles morbillivirus Species 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 206010043376 Tetanus Diseases 0.000 claims description 3
- 230000002584 immunomodulator Effects 0.000 claims description 3
- 210000001165 lymph node Anatomy 0.000 claims description 3
- 201000004792 malaria Diseases 0.000 claims description 3
- -1 mterleukins Proteins 0.000 claims description 3
- 210000001986 peyer's patch Anatomy 0.000 claims description 3
- 239000013600 plasmid vector Substances 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000008072 Lymphokines Human genes 0.000 claims description 2
- 108010074338 Lymphokines Proteins 0.000 claims description 2
- 241000711386 Mumps virus Species 0.000 claims description 2
- 102000029797 Prion Human genes 0.000 claims description 2
- 108091000054 Prion Proteins 0.000 claims description 2
- 210000002534 adenoid Anatomy 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 206010013023 diphtheria Diseases 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 229940047124 interferons Drugs 0.000 claims description 2
- 230000002934 lysing effect Effects 0.000 claims description 2
- 229940021747 therapeutic vaccine Drugs 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 abstract description 19
- 108091033319 polynucleotide Proteins 0.000 abstract description 15
- 102000040430 polynucleotide Human genes 0.000 abstract description 15
- 238000012546 transfer Methods 0.000 abstract description 11
- 230000001580 bacterial effect Effects 0.000 abstract description 7
- 230000010837 receptor-mediated endocytosis Effects 0.000 abstract description 4
- 230000003612 virological effect Effects 0.000 abstract description 4
- 230000002538 fungal effect Effects 0.000 abstract description 3
- 230000003071 parasitic effect Effects 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 86
- 108020004414 DNA Proteins 0.000 description 44
- 108010041986 DNA Vaccines Proteins 0.000 description 27
- 229940021995 DNA vaccine Drugs 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 19
- 238000002649 immunization Methods 0.000 description 18
- 230000004044 response Effects 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 230000001939 inductive effect Effects 0.000 description 13
- 244000052769 pathogen Species 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 11
- 241000725303 Human immunodeficiency virus Species 0.000 description 11
- 230000001717 pathogenic effect Effects 0.000 description 11
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 108010005774 beta-Galactosidase Proteins 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 241000283726 Bison Species 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 108700008625 Reporter Genes Proteins 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical group O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101000575173 Homo sapiens 60S ribosomal protein L12 Proteins 0.000 description 5
- 101000659995 Homo sapiens Ribosomal L1 domain-containing protein 1 Proteins 0.000 description 5
- 101710167241 Intimin Proteins 0.000 description 5
- 108090001090 Lectins Proteins 0.000 description 5
- 102000004856 Lectins Human genes 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000002523 lectin Substances 0.000 description 5
- 210000003563 lymphoid tissue Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 102000004338 Transferrin Human genes 0.000 description 4
- 108090000901 Transferrin Proteins 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 102000005936 beta-Galactosidase Human genes 0.000 description 4
- 108091006004 biotinylated proteins Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001461 cytolytic effect Effects 0.000 description 4
- 244000000021 enteric pathogen Species 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
- 230000016379 mucosal immune response Effects 0.000 description 4
- 150000003839 salts Chemical group 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000012581 transferrin Substances 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000589562 Brucella Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229960003677 chloroquine Drugs 0.000 description 3
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102100025643 60S ribosomal protein L12 Human genes 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 101710198693 Invasin Proteins 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241001480504 Mammalian orthoreovirus 1 Species 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000003254 palate Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- DPISVYSMNIFXGB-UHFFFAOYSA-N 2-(9h-carbazol-3-yl)ethanamine Chemical compound C1=CC=C2C3=CC(CCN)=CC=C3NC2=C1 DPISVYSMNIFXGB-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- FDMDNIIUCZHKFE-UHFFFAOYSA-N 2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethanamine Chemical compound CN(C)CC1=NC(CSCCN)=CS1 FDMDNIIUCZHKFE-UHFFFAOYSA-N 0.000 description 1
- PMNLUUOXGOOLSP-UHFFFAOYSA-M 2-sulfanylpropanoate Chemical compound CC(S)C([O-])=O PMNLUUOXGOOLSP-UHFFFAOYSA-M 0.000 description 1
- APCLRHPWFCQIMG-UHFFFAOYSA-N 4-(5,6-dimethoxy-1-benzothiophen-2-yl)-4-oxobutanoic acid Chemical compound C1=C(OC)C(OC)=CC2=C1SC(C(=O)CCC(O)=O)=C2 APCLRHPWFCQIMG-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 108010071023 Bacterial Outer Membrane Proteins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000222732 Leishmania major Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 229940125791 MSA-2 Drugs 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 241001480506 Mammalian orthoreovirus 2 Species 0.000 description 1
- 241001480512 Mammalian orthoreovirus 3 Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 101710162106 Merozoite surface antigen 2 Proteins 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 102000017033 Porins Human genes 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 description 1
- 102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010084541 asialoorosomucoid Proteins 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005004 lymphoid follicle Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000003126 m-cell Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 108700007621 mifamurtide Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000018889 transepithelial transport Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention is in the general field of vaccine development.
- the present invention is in the general field of vaccine development.
- infectious agents or cancer for human, livestock, and wildlife More specifically, the
- present invention provides DNA vaccines directed to follicle-associated epithelium. Even
- the invention is directed to polycation conjugated M cell ligand (e.g.,
- enteric adheins enteric adheins
- DNA complex vaccine compositions and diagnostic and therapeutic uses
- HSV simplex virus
- HIV-l Boyer
- rotavirus Herrmann et al, Jlnfec Dis (1996) 174(Suppl.l):S93-S97 and Chen et al, J Virol
- DNA immunization has a number of attractive features including ease of
- adjuvant e.g., cytokines
- peripheral sites e.g., intradermal or intramuscular sites. While these methods can elicit
- mucosal immunity i.e., both antibody, particularly IgA, and cellular (cytotoxic T
- lymphocyte (CTL) immunity induction TTL lymphocyte (CTL) immunity induction
- Transepithelial transport of antigens and pathogens is the first step in the induction
- Mucosal inductive tissues are sites in the small intestine or
- mucosal lymphocytes for the development of mucosal immunity
- M cells a specialized lymphoid tissue barrier to the underlying lymphoid tissue.
- epithelium would be advantageous from both investigational and therapeutic standpoints.
- drugs can be a powerful aid to route compounds to a certain target population.
- insulin Sobolev et al, JBiol Chem (1998) 273 -.7928-7933) and would include receptor
- carrier complex can be designed for cell-specific targeting by selecting the appropriate receptor ligand. For example, efficient transfer of DNA to the intestinal epithelial cells by
- transferrin-polylysine conjugates and M cell lectins have been used to successfully transfect
- M cells or follicle associated epithelium are not restricted to M cells or follicle associated epithelium and as M cell lectins
- enteropathic Escherichia coli induces EEC.
- EEC enteropathic Escherichia coli
- Reovirus is an enteric pathogen and infects the host following attachment to
- the protein ⁇ l is a 45
- This invention exploits receptor mediated endocytosis as a means of introducing
- M cell ligands chemically coupling M cell ligands to a polymeric chain of basic amino acids (e.g.,
- DNA can be delivered to appropriate tissue types to obtain enhanced in vivo
- HIV human immunodeficiency virus
- Brucella in vivo.
- the mucosa shows the ability of the protein ⁇ l to mediate efficient gene transfer to the nasal-associated lymphoid tissue (NALT) in vivo.
- NALT nasal-associated lymphoid tissue
- the present invention is based, in part, on the observation that a DNA vaccine
- constructs show improved mucosal IgA antibody responses when compared to DNA applied
- the present invention is further based on the induced anti-
- DNA vaccines to specific cells of the follicle associated epithelium, preferably M-cells, for
- DNA vaccine compositions comprising a polypeptide (or other complexing agent) linked
- polypeptide-DNA complexes in which the polypeptide is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-N-DNA complexe
- the DNA structural sequence preferably encodes an immunogenic antigen from an
- infectious agent but also may encode other immunogens, such as a tumor specific antigen,
- the present invention provides the ability to
- infectious agent be it bacterial, fungal, viral, protozoan, parasitic or protective molecule
- an M cell specific ligand includes an M cell specific ligand, a nucleic acid sequence encoding an immunogen, and a
- nucleic acid binding moiety Preferably, the nucleic acid will be DNA although RNA
- the binding moiety preferably is a polypeptide, however, other
- binding and complexing agents may be utilized so long as they stabilize or protect the
- nucleic acid and protein components of the vaccine from degradtaion and facilitate their
- a polypeptide binding moiety preferably comprises a polymeric chain of basic
- amino acid residues and a contemplated polymeric chain would comprise polylysine.
- the M cell specific ligand is selected from the group consisting of the
- protein ⁇ l of a reovirus or is (or is derived from) an adhesin of Salmonella or a polio virus.
- a polypeptide binding moiety would further comprise an M cell specific
- ligand and may be expressed as a fusion protein.
- nucleotide vaccines in which the immunogen to be delivered
- an immunogen expressed by an infectious agent such as a
- immunogens are derived from or,
- tuberculobacillus tuberculobacillus, leprosy bacillus, malaria parasite, diphtheria bacillus, tetanus
- immunogen and are operably linked to transcription regulatory elements are a preferred
- the vaccines of the present invention are preferably formulated with a
- contemplated immunomodulators include cytokines, lymphokines,
- these vaccines induce a protective
- contemplated vaccines will tolerize a host vaccinated against appropriate
- administration through a route selected from the group consisting of oral, nasal, vaginal,
- nucleotide vaccines as
- assaying for mucosal immunity comprising the steps of administering the vaccine to an
- antigen expressing cells In this assay, lysing of antigen expressing cells is indicative of
- mucosal B cells example mucosal B cells, T cells, lamina intestinal isolates, mtraepithelial isolates, Peyer's
- a fusion protein comprising a nucleic acid binding moiety and an M cell specific
- the binding moiety encodes a polymeric chain of basic amino
- nucleic acids such as polylysine.
- Associated vectors comprising these nucleic acids, such as
- Contemplated nucleic acids would be in an operable linkage, and would include both sense and antisense
- polypeptides comprising a
- the immunogen also serves as a nucleic acid binding moiety and an M cell specific ligand.
- the immunogen also serves as a promoter for cleavage of the immunogen.
- antibodies may be encoded by such fusion proteins. It is also contemplated that antibodies may be
- test purposes that include an M cell specific ligand and a nucleic acid binding moiety
- Figure 1 shows that our recombinant reovirus protein ⁇ l can bind murine nasal M
- FIG. 1 shows sustained mucosal IgA responses against the reporter gene product
- Figure 3 shows induced cytolytic T cell responses against the reporter gene product
- FIG. 4 shows the mucosal intestinal IgA response of mice immunized with one of
- HIN D ⁇ A vaccine constructs presenting gpl60, gpl40(c) or gp 140(s).
- Figure 5A and 5B show enhanced cytolytic activity (cell-mediated immunity) against
- adjuvant refers to a substance added to a vaccine to
- antibody refers to an immunoglobulin molecule that has a
- Antibodies are classified according to their mode of action as
- the tenn "antigen" refers to a substance recognized as foreign by the
- immune system and can be an immunogen.
- DNA vaccine specifically refers to a therapeutic or
- prophylactic pharmaceutical formulation that contains a nucleic acid that encodes a protein
- such a DNA vaccine contains a
- plasmid nucleic acids may be encoded in plasmid nucleic acids.
- enteric adhesin refers to a peptide, protein, carbohydrate
- expression refers to the expression of peptides or proteins
- the DNA vaccine or associated delivery vector that are encoded by, for example, the DNA vaccine or associated delivery vector.
- immunogen refers to a process that increases or
- immunogen refers to a antigen that is capable of eliciting
- an immunogen usually has a fairly high
- infectious agent refers to a microorganism (or associated with
- ligand refers to any molecule that binds to another
- a soluble molecule such as a hormone or neurofransmitter, that binds to a
- M cell(s) and “follicle associated epithelium” refer to
- MALT mucosal associated lymphoreticular tissue
- GALT associated lymphoid tissue
- BALT bronchus associated lymphoid tissue
- NALT lymphoid tissue
- M cell specific ligand refers to a molecule that selectively
- enteric adhesin protein ⁇ l of reovirus
- transferrin and certain other M cell lectins are not
- the transferrin receptor is not limited to M
- carbohydrates with said linkages which are not follicle associated epithelium cells (e.g.,
- the M cell specific ligands are preferred.
- membrane refers to any membrane surface in a host
- organism preferably a mammal such as a human being or agriculturally important animal
- nucleic acid includes DNA and RNA molecules and is
- nucleic acid sequence and “polynucleotide.”
- nucleic acid binding moiety refers to compositions and
- Polybasic chains of amino acids are particularly contemplated for this purpose, as are, for example, synthetic
- polymeric chain refers to compounds formed by the joining of
- polymeric chain of basic amino acids i.e., polybasic
- DNA binding sequence that is rich in basic amino acids, such as lysine, arginine,
- amino acids are suitable so long as the length of the stretch of basic amino acids is within
- the polymeric chain of basic amino acids can be a homopolymer of a
- basic amino acid or it can comprise more than one kind of basic amino acid residue.
- polypeptide refers to an amino acid sequence including, but not
- proteins and protein fragments are proteins and protein fragments, naturally derived or synthetically produced.
- reovirus refers to a genus of the family Reoviridae
- reovirus 1 is the type species.
- transcriptional factors refer to a class of proteins that bind
- tumor specific immunogens refer to immunogens that are
- tumor cells preferentially expressed by tumor cells, more preferably immunogens that are selectively
- vaccination refers to the introduction of vaccine into the
- vaccine generally refers to a therapeutic or prophylactic
- an immune response preferably a protective immune response.
- such a component would be a protein encoded by nucleic acids that is expressed
- This invention provides DNA vaccines, preferably polybasic-M cell ligand
- conjugate-polynucleotide complexes which, when directly introduced into a vertebrate in
- the present invention is based, in part, on the ability of
- Mucosal inductive tissues are sites within the mucosa that support the development of B and
- T lymphocytes to become stimulated against a specific pathogen or vaccine component
- compositions and methods To specifically induce such a mucosal immune response, the compositions and
- methods of the present invention employ ligands formulated to preferentially or specifically
- M target the specialized epithelium that surrounds mucosal inductive tissues referred to as M
- a ligand binds M cells to mediate internalization of the dislcosed DNA vaccine.
- the M cell ligand is an adhesin of a pathogen, preferably an enteric
- adhesin of a pathogen such as a ⁇ l protein of a reovirus. Additionally, adhesins from
- Salmonella and poliovirus as well as other infectious agents having the same tissue tropism
- nucleotide sequences encoding said proteins would be appropriate.
- nucleotide sequences encoding said proteins would be appropriate.
- the immunogen may be an enteric adhesin of a pathogen
- nucleotide 1 such as an intimin of an enteropathic Escherichia coli.
- nucleotide 1 such as an intimin of an enteropathic Escherichia coli.
- sequences encoding said intimin protein include but are not limited to polynucleotides
- immunogen is an enteric adhesin receptor of a pathogen such as an Tir of an enteropathic Escherichia coli.
- pathogen such as an Tir of an enteropathic Escherichia coli.
- protem include but are not limited to polynucleotides comprising nucleotide sequences as
- the immunogen is an
- enteric adhesin of a pathogen such as an invasin of Salmonella typhimurium, Yersinia pestis
- nucleotide sequence for example, the nucleotide
- sequences encoding said invasin proteins include but are not limited to polynucleotides
- nucleotide sequences as set forth in accession numbers: AF140550; Z48169;
- a contemplated polynucleotide is a nucleic acid which
- the polynucleotide is a polydeoxyribonucleic acid comprising immunogen (or
- polynucleotide comprises
- ribosomes amenable to translation by the eukaryotic cellular machinery (ribosomes, tRNAs, and other
- HIN human immunodeficiency virus
- the animals' immune system is activated to launch a protective immune response.
- MHC major histocompatibility system
- polynucleotide generating immune responses to an encoded protein are referred to herein as polynucleotide
- the described vaccine works by inducing the vaccinated animal to
- the present formulations encoding various selected antigens may be administered to
- tuberculosis e.g., BCG
- malaria e.g., surface antigen
- MSA-2 Pye et al, Vaccine (1997) 15(9):1017-1023), diptheria (e.g., diptheria toxoid: U.S. Patent No. 4,691,006 ), tetanus (e.g., tetanus toxin: Fairweather et al, Infect Immun (1987)
- leishmania e.g., Leishmania major promastigotes: Lasri et al, Vet Res.
- salmonella e.g., covalently bound capsular polysaccharide (Ni) with
- schistomiasis e.g., major antigen of Schistosoma mansoni (Sm28 GST): Auriault et al,
- measles e.g., the surface glycoprotein and fusion protein of
- mumps e.g., mumps
- H ⁇ hemagglutinin-neuraminidase
- herpes e.g., HSN-2 surface glycoproteins (gB2 and gD2): Corey et al,
- influenza e.g., immunodommant peptide from hemagglutinin: Novak
- the present invention further provides recombinant DNA molecules (rDNAs) that
- the vaccines are produced using conventional eukaryotic cells.
- a rDNA molecule is a
- a vector contemplated by the present invention is at least capable of
- Expression control elements that are used for regulating the expression of an
- operably linked protein encoding sequence include, but are not
- inducible promoters are limited to, inducible promoters, constitutive promoters, secretion signals, and other regulatory elements.
- the inducible promoter is readily controlled, such as being
- the vector containing a coding nucleic acid molecule will be any suitable nucleic acid molecule.
- prokaryotic replicon i.e., a DNA sequence having the ability to direct autonomous
- prokaryotic host cell such as a bacterial host cell, transformed therewith.
- prokaryotic host cell such as a bacterial host cell
- vectors that include a prokaryotic replicon may also be used.
- a gene whose expression confers a detectable marker such as a drug resistance include a gene whose expression confers a detectable marker such as a drug resistance.
- Typical bacterial drug resistance genes are those that confer resistance to ampicillin or tetracycline.
- Vectors that include a prokaryotic replicon can further include a prokaryotic or
- a bacteriophage promoter capable of directing the expression (transcription and translation) of the coding gene sequences in a bacterial host cell, such as E. coli.
- a promoter is an expression
- control element formed by a DNA sequence that permits binding of RNA polymerase and
- Promoter sequences compatible with bacterial hosts are typically
- vector plasmids Typical of such vector plasmids are pUC8, pUC9, pBR322
- Expression vectors compatible with eukaryotic cells preferably those compatible with
- vertebrate cells can also be used to form a rDNA molecules that contains a coding sequence.
- Eukaryotic cell expression vectors are well known in the art and are available from several sources.
- Typical of such vectors are pSVL and pKSV-10
- Eukaryotic cell expression vectors used to construct the DNA vaccine molecules of the
- present invention may further include a selectable marker that is effective in an eukaryotic cell,
- a preferred drug resistance marker is the gene
- neomycin phosphotransferase neomycin phosphotransferase
- the marker can be present on a separate plasmid, and the two vectors are introduced by co- transfection of the host cell, and selected by culturing in the appropriate drag for the selectable
- the M cell ligand-polybasic conjugates according to the invention may be produced
- coupling may be carried out by means of various techniques Icnown to persons skilled in
- nucleic acid molecule that encodes an M cell ligand protein of the
- nucleic acid molecule is then preferably placed in operable linkage
- the expression unit is used to transform a suitable host and the
- transformed host is cultured under conditions that allow the production of the recombinant
- the recombinant protein is isolated from the medium or from the cells;
- coding sequences may be obtained from genomic fragments and used directly in appropriate
- sequences, expression vectors, and transformation methods are dependent on the type of host
- Suitable restriction sites can, if
- the polybasic components may vary in terms of their size and amino acid sequence.
- the conjugate to be modified by increasing the ability to bind to the receptor, by suitable
- express plasmids can be obtained, of which the plasmid containing the desired sequence can be
- the nucleic acids which are to be transported into the cell may be DNAs or RNAs, with
- nucleic acids may be modified, provided that
- ligand-polybasic conjugates can be efficiently absorbed into living cells and internalized.
- conjugates or complexes according to the invention are not apparently harmful to cell
- the ratio of nucleic acid to conjugate can vary within a wide range, and it is not
- nucleic acid which is to be transported the size of the polybasic component and the number and
- nucleic acid which is favorable to the particular appUcation. This ratio can first of all be adjusted
- negative charges of the nucleic acid are not an obstacle to transportation into the cell.
- precipitation is to mix the two components together first of all at a high (about 1 molar)
- complex according to the invention is an immunogen structural gene encoded by the nucleic acid
- the invention further relates to a process for introducing nucleic acid or acids into human
- Antibodies against M cell ligand-polybasic moiety protein conjugate or complex may be
- linking reagents such as those supplied by Pierce Chemical Co., Rockford, IL,
- the hapten peptides can be extended at
- hnmortaUzed cell lines which secrete the desired monoclonal antibodies may be prepared using
- lymphocytes or spleen cells as is generally known.
- desired antibodies are screened by immunoassay in which the antigen is the peptide hapten,
- the cells can be cultured either in vitro or by production in ascites fluid.
- the desired monoclonal antibodies are then recovered from the culture supernatant or
- fragments is often preferable, especially in a therapeutic context, as these fragments are generally
- the antibodies or fragments may also be produced, using current technology, by
- antibodies specific for the M cell ligand polybasic moiety conjugate can also be produced in the context of chimeras with multiple species origin.
- antibodies specific for the M cell ligand polybasic moiety conjugate can also be produced in the context of chimeras with multiple species origin.
- antibodies specific for the M cell ligand polybasic moiety conjugate can also be produced in the context of chimeras with multiple species origin.
- antibodies specific for the M cell ligand polybasic moiety conjugate can be produced in the context of chimeras with multiple species origin.
- carrier vectors or specific gene sequences may be used successfully.
- Various methods are
- encoding a protein can be produced which alter the amino acid sequence of the encoded protein.
- amino acids are tolerated without affecting protein function. Similar amino acids can be those
- isoleucine and valine are both pairs of similar amino acids. Similarity between amino acid pairs
- the altered expressed protein may have an altered amino acid sequence, yet still eUcits immune responses which react with the antigen protein, and
- fragments should encode a protein or peptide which eUcits antibodies that crossreact with the
- immunogenic protein and are considered to be functional equivalents.
- the amount of expressible DNA or transcribed RNA to be introduced into a vaccine is the amount of expressible DNA or transcribed RNA to be introduced into a vaccine
- transcriptional and translational promoters used as well as subject size, e.g., human versus bison
- immune response may depend on the level of protein expression and on the immunogenicity of
- an effective dose ranges of about 1 ng to 5 mg, 100 ng to
- mterleukin-12 protein or other
- cytokines e.g. GM-CSF
- the polynucleotide may be associated with adjuvants or other agents which affect the
- the formulation it is desirable for the formulation to be in a
- physiologically acceptable solution such as, but not limited to, sterile saline or sterile buffered saUne.
- active immunogenic ingredients can be mixed with excipients or carriers which are
- the DNA vaccine complexes may contain minor amounts of
- auxiUary substances such as wetting or emulsifying agents, pH buffering agents, and/or
- adjuvants which enhance the effectiveness of the vaccine.
- adjuvants wliich may be any adjuvant.
- CGP 11637 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP);
- CGP 19835A referred to as MTP-PE
- RIBI which contains three components extracted from bacteria, monophosphoryl Upid A,
- the effectiveness of an adjuvant may be determined by measuring the amount of
- vaccines wliich are also comprised of the various adjuvants. Such additional formulations and
- the DNA vaccines of the present invention may be formulated into compositions as
- compositions include but are not limited to the acid
- addition salts formed with free amino groups of the peptide which are formed with inorganic acids, e.g., hydrochloric acid or phosphoric acids; and organic acids, e.g., acetic, oxalic, tartaric,
- Salts formed with the free carboxyl groups may also be derived from inorganic
- bases e.g., sodium, potassium, ammonium, calcium, or ferric hydroxides, and organic bases,
- isopropylarnine trimethylamine
- 2-ethylamino-ethanol histidine
- procaine e.g., isopropylarnine, trimethylamine, 2-ethylamino-ethanol, histidine, andprocaine.
- the M cell ligand-polybasic moiety (or conjugate)-polynucleotide compositions are provided.
- Precise amounts of the active ingredient required to be administered may depend on the
- the DNA vaccines of the present invention may be given in a single dose or multiple
- a multiple dose schedule is one in which a primary course of vaccination may
- intervals as required to maintain and or reinforce the immune response e.g., at 1 to 4 months for
- the vaccines of the present invention are useful for administration to domesticated or
- Vaccines of the present invention may be used to treat agricultural animals, as well as humans.
- Vaccines of the present invention may be used to treat livestock, as well as humans.
- MBP maltose-binding protein
- fusion protein was purified by affinity chromatography using amylose resin according to
- recombinant protein ⁇ l referred to as recombinant protein ⁇ l .
- Example 2 Preparation of recombinant fusion protein ⁇ l-polylysine-DNA complex
- the recombinant protein ⁇ l was covalently linked to poly-L-lysine (PL) according
- SPDP succinimidyl 3-(2-pyridyldithio)propionate
- modified protein ⁇ 1 was then mixed with the 20 mg of mercaptopropionate-modified PL under
- MBP-PL conjugates were similarly generated.
- conjugate- DNA complex the protein ⁇ l-PL conjugate in 125 ⁇ l of HS was added dropwise into an equal
- mice L cells were incubated with mouse L cells (CCL-1, American Type Culture Collection, Manassas, VA),
- RFL-6 fibroblast cells (CCL-192, ATCC), and Caco-2 cells (HTB-37, ATCC) and binding was
- biotinylated monoclonal anti-reo virus protein ⁇ l antibody (HB-167,
- the mouse L cells, RFL-6 cells, and Caco-2 cells were used for targeting gene
- the mouse L cells have been used as the in vitro model for
- DMEM lninimiim essential medium
- conjugate-DNA complexes were removed, and cells were incubated with complete media for
- DNA complexes containing 8 ⁇ g ⁇ l-PL and pCMV ⁇ -gal (Life Technologies), with or without
- chloroquine were added and incubated for 24 hours. The cells were then incubated with fresh
- the Luc gene was used as a reporter gene to assay protein ⁇ l-PL conjugate-
- pCMVLuc was
- FDG fluorescein-mono- ⁇ -D-galactopyranoside
- NALT were incubated with excess unmodified protein ⁇ l in order to inhibit biotinylated protein
- Tissue Tek @ Cryomold (Miles Inc., Elkhard, IN) with their ventral surfaces oriented toward the bottom of the mold. The palates were then frozen in Tissue
- Example 7 In vivo analysis of intranasal immunization with ⁇ l conjugates
- mice induced mucosal IgA responses in mice.
- Data depicts the mean endpoint titers ( ⁇ SE) for mice
- mice/group Significant differences between protein ⁇ l-PL-pCMVLuc and pCMVLuc only
- mice received three i.n.
- mice The mean endpoint liters ( ⁇ SE) for mice
- mice were immunized with one of three designated HJV D ⁇ A vaccine
- mice/group received three intranasal immunizations either of naked D ⁇ A or of the identified M
- the D ⁇ Avaccine formulation improved mucosal IgA responses when compared to
- mice received a formulated vaccine, naked D ⁇ A version, protein
- mice i.n. -immunized with the formulated vaccine as opposed to mice immunized with the naked D ⁇ A alone.
- Pulmonary lymph nodes (LRL ⁇ ) and splenocytes from immunized mice were restimulated in vitro with cells expressing gpl20 or beta-galactosidase (neg. control), and were subsequently examined for cytolytic activity. The observed killing was specific since negative
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01901811A EP1257654A1 (en) | 2000-01-06 | 2001-01-08 | M cell directed vaccines |
US10/169,492 US20040033486A1 (en) | 2001-01-08 | 2001-01-08 | M cell directed vaccines |
AU27672/01A AU2767201A (en) | 2000-01-06 | 2001-01-08 | M cell directed vaccines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17478600P | 2000-01-06 | 2000-01-06 | |
US60/174,786 | 2000-01-06 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/169,492 A-371-Of-International US20040033486A1 (en) | 2000-01-06 | 2001-01-08 | M cell directed vaccines |
US10/660,787 Continuation-In-Part US20040109871A1 (en) | 2000-01-06 | 2003-09-12 | M cell directed vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001049867A1 true WO2001049867A1 (en) | 2001-07-12 |
Family
ID=22637521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/000426 WO2001049867A1 (en) | 2000-01-06 | 2001-01-08 | M cell directed vaccines |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1257654A1 (en) |
AU (1) | AU2767201A (en) |
WO (1) | WO2001049867A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2460969A (en) * | 2004-06-23 | 2009-12-23 | Ian A Ferguson | Nasally-administered vaccines |
AU2012201102B2 (en) * | 2004-06-23 | 2014-05-08 | Ferguson, Ian Andrew | Agents and methods for early diagnosis and monitoring of Alzheimer's disease and other neurological disorders |
-
2001
- 2001-01-08 EP EP01901811A patent/EP1257654A1/en not_active Withdrawn
- 2001-01-08 AU AU27672/01A patent/AU2767201A/en not_active Abandoned
- 2001-01-08 WO PCT/US2001/000426 patent/WO2001049867A1/en not_active Application Discontinuation
Non-Patent Citations (7)
Title |
---|
FREY A ET AL: "Targeting of mucosal vaccines to Peyer's patch M cells.", BEHRING INSTITUTE MITTEILUNGEN, (1997 FEB) (98) 376-89. REF: 69, XP000995438 * |
GIANNASCA P.J. ET AL: "Targeted delivery of antigen to hamster nasal lymphoid tissue with M - cell -directed lectins.", INFECTION AND IMMUNITY, (1997) 65/10 (4288-4298)., XP000995425 * |
HADDAD, A. (1) ET AL: "Targeted M cell immunization for HIV-1 ENV DNA vaccines.", FASEB JOURNAL, (APRIL 20, 2000) VOL. 14, NO. 6, PP. A1204. PRINT. MEETING INFO.: JOINT ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS AND THE CLINICAL IMMUNOLOGY SOCIETY SEATTLE, WASHINGTON, USA MAY 12-16, 2000, XP000995418 * |
NEUTRA, MARIAN R. ET AL: "Antigen uptake by M cells for effective mucosal vaccines", MUCOSAL VACCINES (1996), 41-55. EDITOR(S): KIYONO, HIROSHI;OGRA, PEARAY L.; MCGHEE, JERRY R. PUBLISHER: ACADEMIC, SAN DIEGO, CALIF., XP000996131 * |
WAGNER E: "TRANSFERRIN-POLYCATION CONJUGATES AS CARRIERS FOR DNA UPTAKE INTO CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 87, no. 9, 1 May 1990 (1990-05-01), pages 3410 - 3414, XP000368690, ISSN: 0027-8424 * |
WANG, X. (1) ET AL: "In vivo induction of cytotoxic T lymphocytes by M cell vaccination.", FASEB JOURNAL, (APRIL 20, 2000) VOL. 14, NO. 6, PP. A1204. PRINT. MEETING INFO.: JOINT ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS AND THE CLINICAL IMMUNOLOGY SOCIETY SEATTLE, WASHINGTON, USA MAY 12-16, 2000, XP000995419 * |
WU Y ET AL: "Gene transfer facilitated by a cellular targeting molecule, reovirus protein sigma1.", GENE THERAPY, (2000 JAN) 7 (1) 61-9., XP000995427 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2460969A (en) * | 2004-06-23 | 2009-12-23 | Ian A Ferguson | Nasally-administered vaccines |
GB2460969B (en) * | 2004-06-23 | 2010-02-17 | Ian A Ferguson | Vaccines for intranasal administration |
AU2012201102B2 (en) * | 2004-06-23 | 2014-05-08 | Ferguson, Ian Andrew | Agents and methods for early diagnosis and monitoring of Alzheimer's disease and other neurological disorders |
Also Published As
Publication number | Publication date |
---|---|
EP1257654A1 (en) | 2002-11-20 |
AU2767201A (en) | 2001-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11104916B2 (en) | Compositions and methods for alphavirus vaccination | |
KR101650364B1 (en) | Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses | |
Ellis | New technologies for making vaccines | |
CN100489105C (en) | Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector | |
Fennelly et al. | Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector | |
US20020025323A1 (en) | Compositions and methods for enhancing immunogenicity of antigens | |
JP2012501959A (en) | Composition comprising Yersinia pestis antigen | |
EP2478915A1 (en) | CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses | |
US6737521B1 (en) | Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria | |
WO2023023940A1 (en) | Immunogen for inducing broad-spectrum anti-coronavirus t cell vaccine and use thereof | |
JP2013520487A (en) | Immunogenic proteins and compositions | |
CN102711815B (en) | Adjuvant for vaccines, vaccines that comprise said adjuvant and uses thereof | |
JP4653934B2 (en) | Bacteriophage mediated immunization methods | |
ES2224097T3 (en) | SUPPLY AND EXPRESSION OF A HYBRID SURFACE PROTEIN ON THE POSITIVE GRAM BACTERIA SURFACE. | |
US20040109871A1 (en) | M cell directed vaccines | |
TW202206598A (en) | A vaccine against sars-cov-2 and preparation thereof | |
Shi et al. | The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization | |
Toussaint et al. | Genetic immunisation of cattle against bovine herpesvirus 1: glycoprotein gD confers higher protection than glycoprotein gC or tegument protein VP8 | |
WO2002072015A2 (en) | M cell directed vaccines | |
Chin et al. | Manipulating systemic and mucosal immune responses with skin-deliverable adjuvants | |
US20040033486A1 (en) | M cell directed vaccines | |
WO2001049867A1 (en) | M cell directed vaccines | |
CN113801206B (en) | Method for inducing neutralizing antibodies against novel coronaviruses using receptor recognition domains | |
JP2002514061A (en) | Compositions and methods for administering pneumococcal DNA | |
Burnette | Recombinant subunit vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001901811 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10169492 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2001901811 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001901811 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |